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l?esu/ts:All investigators were sent a questionnaire concerning vital status
and heart transplantation for each patient 3 years after inclusion in the MDC
trial. Data regarding survival and heart transplantation were obtained in 318
of 383 patients. During the MDC-trial there were 44 deaths (21 placebo and
23 metoprolol). During the 3-year follow-up there were another 27 endpoints
in the patients originally receiving placebo (15 transplantations, 12 deaths),
and 17endpointa in the patients originally on metoprolol (13 transplantations,
4deaths). Transplantation-frw survival was 108 of 135 in the placebo group,
and 122 of 139 in the metoprolol group.
Corrchrs/on.’Although many patients received open treatment with beta-
blockade after the double blind phase of the study, the original trend toward
improved transplantation-free survival was maintained 3 years,after inclusion
In the study. Thus, beta-blockade treatment may induce beneficial effects on
myocardlal recovety that postpone future deterioration.
u ,at,en,8”996-55 Tolerability of Carvediioi Initiation in Heart Faiiure
M.B. Fowler, W.S. Colucci, M.R. Brlstow, M. Packer, E.M. Gilbert,
J.N. Cohn, B. WU,J.Z. Hu, M.A. Lukes, S. Kubo, R. Hershberger,
S. Gottlieb, 1.Pina, for the US Carvedllol Heart Failure Study Group.
Stanford Univerai~, Palo Alto, CA, USA
Instituting p-blockade in heatt failure patients (pts) can be associated with
worsening clinical status orother signs of intolerance. Carvadilol (C), combin-
ing nonselective p-and m+blockade with antioxidant effects, showed benefi-
cial effects on clinioal status, survival and morbidity in the US Carvedilol Heart
Failure Trials Program (NYHA II-IV pts with EF < 35% receiving digoxin, di-
uretics ancflor ACEI). We examined the study population retrospectively as
to the incidence of tolerating initiation. Open challenge”wlth C (mean 14 + 5
days) was followed by Minded (C or placebo) titration to target doses (TD) of
6.25 to 50 mg tWiGedaily.
Results: Initial C dose was 6.25 mg in 97% of 1197 pts challenged; 3%
began at, and 7% at some point received 3.125 mg bid during initiation.
Challenge withdrawals for safety were 5% (worsening CHF 2%, dizziness
1.1%, bradycardia 0.2Y0, death 0.57., other event 1.2%). During blinded
titration (C, 696: placebc, 398), 7SY. and 81% reached target dose, with
2.4Y0and 1.1% withdrawn for adverse event, respectively.Reducing diuretic
dose occurred in 8% of C pts but only 3% of pts on placebo. The incidence of
increasing diuretic or changing ACE dose, or mean up-titration days (19.3)
did not differ between C and placebo.
Conclusion: Target carvedilol dose can be successfully reached in most
heart failure pts. Adjustment of other medication, especially decreasing di-
uretic, may be needed in some patients.
D99656 Moxonidine improvea Heart Rete Variability inPatienta With Heart Faiiure
S.Juul-M611er,K. Swedbarg, K. Dickstein, J. McNay. Ma/mo University
Hospital, Malmo, Sweden
Reduced heart rate variability (HRV) reflects autonomic abnormalities and
carries a negative prognosis in heart failure (HF). Intervention with digitalis,
ACE inhibitora, beta blw”kera, and exercise training improves morbidity and
HRV in patients with HF. 96 patients with NYHA II-HI HF and EF-less than
40% on standard treatment were randomized to receive placebo (P) or
moxonidine (M) 0.1, 0.2 or 0.3 mg bid for three months in a multicenter,
double-blind study. 24 hour Helter ECGS were recorded at pretreatment
baseline and 11weeks.
Average changes were:
Doea,mgbid P 0.1 0.2 0.3
N* 19 22 28 t9
A 24 hr HR**, bpm 1 –1.6 –2.1 –3.6
A SDR-R***,ms 2, 2 10 tz
A PNE**”*,p~mi 185 -32 –41 –48
*Complaterewith NSRwithoutpacemaker;“*HR= heartrate;***SDR-R=atanrtardrJe-
vlatkmof5 minepochsofR-Rintervals;****pNE= ~lasmanorepinephrine
There were correlations between dosage of M and: decrease in HR (P=
0.0S),increase indaytifne SD R-R (P c 0.04) and decrease in PNE (P < 0.01).
We conclude that the increase in HRV and decrease in HR are consistent
with sympathetic inhibition confirmed by reduction in PNE. Moxonidine has
potential therapeutic value due to improvement in autonomic abnormalities
of HF.
m EfiWtSOfCOmbine& Therap~with*CElnhibition
and Angiotenain-il ATI Receptor Biockade in
Moderate Heart Faiiure
M. Tanimura, S. Shevlyagin, H. Shimoyama, S. Goldstein, H.N. Sabbah.
Henry Ford HeWand Vascu/arhrstitute Detroit, M/, USA
Long-term therapy with the ACE inhibitor enalaprii (ENA) was shown to at-
tenuate the progression of LVdysfunction in dogs with moderate heart failure
(HF). In the present study we determined whether combined therapy with
ENA and MK996, an angiotensin-11ATi receptor blocker, is more effective
in improving LV function and chamber remodeling than ENA alone. Stud-
ies were performed in 20 dogs with moderate HF (LV ejection fraction, EF =
35%-400A)produced by intracoronaty mlcroembcdlzations.Seven dogs were
treated for 3 months with ENA (10 mg Bid), 6 with ENA (10 mg Bid) plus
MK996 (5 mg Bid), and 7 were untreated (CON). In all dogs, mean aonic
pressure (MAP), LV EF,end-diastolic (EDV) and end-systolic (ESV) volumes
were measured before and after 3 months of therapy and the change (A) for
each parameter was calculated.
CON ENA ENA+ MK996
A MAP(mmHg) 14+6 -4 * 7 -24 k 7’
A LVEF(%) –10+ 1 3+3* 1l 1“
A LVEDV(ml) 16+3 4 *2* -1 *I*
A LVESV(ml) 18+3 1 * 3“ –1 l 1“
*P <0.01 VS.CON
Despite a marked reduction in MAP, combined therapy with ENA and
MK996 was similar to ENA alone in its ability to prevent the progressive da-
ciinein EFand the increase in EDV and ESV seen in CON dogs. Cone/us/on:
In dogs with moderate HF,combining ATI receptor blockade therapy to ACE
inhibition does not improve LVfunction and remodeling beyond that accrued
by ACE inhibition alone.
1996-701 Differen.esBeWeenReapOn*e*t~~ei~~iPinein
Heart Faiiure With and Without Coronary Disease:
V-HeFT iii
J.N. Cohn, T. Germanson, S. Ziesche, for the V-HeFT Study Group.
Minneapolis, MN, USA
Recent data have suggested the possibility of a differential therapeutic re-
sponse in heart failure due to corona~ disease (CAD), and non-ischemic
cardiomyopathy (non-CAD). The V-HeFT Ill data base was examined to
compare the response to the calcium antagonist felodipine 5 mg b.i.d. in
these populations.
Baseline observations:
CAD NON-CAD
246 204
lge (years) 64.5 61 .9”
Race (% white) 82 62*
Hypertensionhistoty(“A) 44 59*
Bloodpressure(S/D mmHg) 121i73 123r75
Heart rate (beattimin) 74.0 75.7
LV EjectionFraction(EF) (“A) 28.1 31 .5”
Exerciasduration(rein) 9,4 9.6
Plasma norepinephrine(pgiml) 508 512
Plasme strialpeptide (p@ml) 122 125
Ventriculartachycardia(%) 60 62
EF increased similarly at3months in responseto felodipine in both groups
(CAD, +1.6; non-CAD, +2.7) vs. placebo (CAD, +0.4, non-CAD, -0.6). There
was a trend for a more favorable response to felodipine at 12 months in non-
CAD than in CAD groups in exercise tolerance (+0.6 vs Orein) and plasma
norepinephrine (–10 p@mlvs. +57 p~ml) despite a similar incidence of new
ventricular tachycardia and no difference in the effect of F on mortality.
Therefore, patients with CAD were older and had a lower EF than non-
CAD heart failure patients. Felodipine exerted a somewhat greater effect on
non-motality end-points in the non-CAD group, but the effects on EF and
motiality were similar.
m BenefiCieiHemOdYnami.~~e.tsofA.u~e
inauiin-Like Growth Factor-1in Patients With
Chronic Heart Faiiure
G. Sutsch, M. Donath, X.-W. Yan, H.-P. Brunner, F. Follath, E.R. Froasch,
W. Kiowski. Cardiology and Endocrinolog~ University Hoapital, Ziirich,
Switzerland
Insulin-1ikegrowth factor-1(IGF) enhances myofibrillar development in vitro
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and in rats and improvea cardiac function in healthy volunteera. hi addition,
IGF has vaaodilator effects. We tested the tolerability and safety but alao the
acute hemodynamic effects of a single IGF infuaion in 8 patients (pta: 47 &
5 years, 1 female, 7 males) with mild to aevere chronic heart failure (mean
left ventricular ejection fraction 26 + 3’7., mean cardiac index [Cl] 2.6 +
0.4 Umin). Recombinant human IGF (60 mdkg of body weight) or matching
solvent were infused intravenously over 4 hours in a croasover, double
blind, randomized fashion on 2 subsequent days while regular medication
was given. Hemodynamics were continuously monitored by ballon-tipped
pulmonary and radial artery catheters, and ECG,respectively, before and
during 7 houra from the atarl of each infusion. IGF was well tolerated in all
pts and plaama glucose and electrolytes were unaffected by IGF.Right atrial,
pulmonary artery and pulmonary capillary wedge pressureawere unchanged
during the 2 study days. Compared to placebo, IGF reduced mean arterial
presaure by 2.6 mmHg [-3.95 to –1.25, p < 0.01] (valuea are means [957.
confidence interval]) and improved Cl by 0.36 Umin [+0.26 to +0.47, p <
0.01] through both an increase in heart rate of 5.8 beats/rein [+3.0 to +8.5,
p < 0.01] as well as of stroke volume index by 2.2 mUmin [+0.66 to +3.77,
p < 0.01], Conaequently, both syatemic and pulmonary vascular resistances
decreased by 204 [-247 to –160, p < 0.01] and 17.9 [–28.0 to –7.8, p <
0.01] dynes sec cm-5, respectively.Thus, acute IGF administration in these
pts is safe and improves cardiac performance seemingly through afterloed
reduction, It remains to be established whether the obaerved acute effects
are maintained and whether enhancement of myofibrila plays a role during
chronic therapy.
a99672 CentralHaemodynamicEffectaof Endothelin-1inPatients with Left Ventricular Dysfunction
P.J.Cowburn, J.D. McArthur, M.R. McLean, J.J.V. McMurray, H.J. Dargie,
J.G.F. Cleland. University of G/asgowand Western Infirmary Glasgow, UK
Plaama levels of endothelin-1 are raiaed in heart failure and are thought to
contribute importantly to pulmonaty vascular resistance in this setting. We
administered endothelin-1 into a distal pulmonary artery of eight patients
with ventricular dysfunction with or without overt heart failure in an attempt
to atudy Imal pulmonary vascular effects. Local pulmonary flow using intra-
vascular Doppler ultrasound was asaessed in the first 4 patients. Central
haemodynamics were meaaured by thermodilution catheter and arterial line.
Endothelin-1 was infuaed at 1, 5 and 15 pmol/min. No side effecta occurred
but 2patienta did not receive the 15 pmol/min infusion due to a rise in syatolic
BP >20 mmHg or a fall in cardiac output of > 15%.
Systemic haemodynamic effects were obsewed with doses that caused
bcal pulmonary vascular effects. Cardiac index fell, doae dependently, from
2.38 +0.59 to 2.16+ 0.55 l/min/m2 (p =0.008) at the maximumadministered
dose. Mean arterial pressure rose from 98+ 7 to 108 +12 mmHg (p = 0.01)
but pulmonaty artery pressures (21 & 7 mmHg) and heart rate (67 + 12
beate/min) did not change. Systemic (1669+ 415t02032 + 478 dyn a cm-5;
p < 0.01) but not pulmona~ (154 * 49 to 147 + 45 dyn a cm-5) vascular
reaiatance rose and the pulmonary to ayatemicvascular resistance ratio fell.
Exogenous endothelin-1 causea systemic but not pulmonaty vasocon-
striction in patientswith Ieftventricular dysfunction. Increasedplasmaendothelin-
1 maybe a biological marker of rather than a cause of pulmona~ hyperten-
sion in heart failure.
1996-73[ De~reased/n~jtrovaa@arProsW,andin~eleaae
to Alpha-1AdrenoceptorStimulationinCHF
Patients
J.M.O. Arnold, M.L. Lembert, I.D. Callow. London Health Sciences Cenfre,
London, Ontario, Canada
Alpha-l adrenoceptorstimulation inyoung normals invivoliberates release of
vaacdilatory proataglandina which antagonize the venoconstrictor response.
We hypothesized that in congestive heart failure (CHF) with endothelial
dysfunction there would be reduced release of vasodilatory prostaglandins
from theendothelium and therefore an increaaedvascular responaetoalpha-
1 stimulation.
Six CHF patients (LVEF 14.2 & 0.9%) and 6 age-similar normals were
studied on 2 daya uaing a hand vein technique to assess in vivo venous
responsiveneas without ayatemic effects. Graded 5 min local infusiona of
phenylephrine (6-12000 ng/min) were administered witha randomlyaelacted
separate infuaion (in the same vein) of either the proateglandin synthesis
blocker indomethacin (3 @rein) or aaline and dose response curves were
constructed of venoua distention at 45 mmHg. Endothelial function was
determined by acetylcholine (0.01-1.0 nmol/min).
Doae-dependent venoconstricfion was obaerved in all aubjects studied.
Maximum dilation to ecetylcholine was 57.3 + 9.7% for normals compared
to 10.6% & 3.0% for CHF patients. In normals, the entire phenylephrine
dose-response curve was significantly (p < 0.05) ahifted to the left with in-
domethacin. However, in CHF the phenylephrine doae-reaponae curve was
unaltered. Therefore the doae of phenylephrine to cause 50% venoconatrfc-
tion was decreased significantly with indomethacin compared with saline in
normals, but not in CHF (1.91 & 0.11vs. 2.77+0,12, p <0,05, normal; 2.37+
0.23 vs. 2.35 + 0.26, CHF; log ng/min & SEM). Thua, endothelial dysfunction
in CHF ia associated with a markedly blunted release in vivo of vasodila-
tory prostaglandins to an alpha-1 agoniat and this mechanism could result in
increased venoconatriction to sympathetic stimulation in patients with CHF.
~996-74[ HemOdYnamicEffecte ofa24hourlnfusionof
B-type Natriuretic Peptide (Natrecor@)in Patients
with Decompensated Heart Failure
R.M, Mills, Jr., T, LeJemtel, K. Chatferjee, C. Liang. University of F/orida
Co//egeofhfedicine, Gainesvi//e, FL, USA, A/beti Einstein Co//ege of
Medicine, Bronx, NY USA
Synthetic B-type Natriuretic Peptide (aBNP) is identical to human BNP. In
patienta (pts)with hearffailure, pharmacologic doses of aBNP have favorable
effects during 4-6 hrs intravenous (IV) infusion, and with repeated IV boluses
over24 hrs. A multicenter, placebo-controlled, randomized, double-blind trial
was initiated to assess the effect of aBNP (15-60 ng/kgJmin)by continuous
IV infusion over 24 hrs vs placebo (PL) in pts with decompenaated heart
failure. Parameter included pulmona~ capillary wedge preaaure (PCWP,
principal endpoint), cardiac index (Cl), systolic blood presaure (SBP) and
heari rate (HR). Meaaurementa were taken at baseline (BL), 6, 10, and 24
hrs of infusion and at 4 hrs peat-infusion (28 hrs). An interim analyais was
performed including the first 50 pta (SBNP, n = 37; PL, n = 13); for this
analysia pts were not divided by dose.
Percentchangefrombaseline(sBNPIPL)
Infusion(hrs) Post (hrs)
6 10 24 4
PCWP -35/–2**-- –3,/+3**- –21/–lo** –1/–9
c1 +39/=1**”- +34/+3””- +261+8’” +14/0
HR –l/+7- -1/+13” +4/+14” +12/+lo**
SBP –a/-2** –4/–1 –61+2**- +1/-1
(**) BNPVS.baseline P less than Orequal to (0.01) (two-aided);“(-”)BNP VS. placeh p
less than or equsl to 0.05 (0.01) (two-sided)
aBNP reduced PCWP and improved Cl over 24 hra without major ad-
verse events, and appears to be a aafe potent agent for improving central
hemodynamics over a 24 hr period.
/996-75]EffWtSOfCarPeritide(~-HIJmanAtrialNatriliretk
Peptide) in Patients with Acute Heart Failure -
Comparative Study on Tolerance Between
Carperitide and Nitroglycerin
H. Watanabe, M. Kakihana’, S. Ohtauka, Y. Sugishita. University of
Tsukuba, Tsukuba,Japan, 1Ibaraki Prefectural University of Health
Sciences, Ibaraki, Japan
Carperitide (aynthetic a-human atrfal natriuretic peptide, ANP) has bean
available as a therapeutic agent for acute heart failure in Japan. This study
was designed to assess the development of tolerance during continuous
administration of carperitide compared with nitroglycerin (NTG). Twelve pa-
tients hospitalized with acute heart failure (Forrestersubset 11)were randomly
assigned to two groups. After stabilization of hemodynamica (control phase),
intravenous infusion of ANP (ANP group, n = 6) or NTG (NTG group, n
= 6) was atatied at a rate of 0.1 @kg/rein, while diuretics and other va-
sodilators were discontinued. The optimum doaages of ANP and NTG wens
determined based on hemodynamic parameters (stage 1). Thereafter, ANP
or NTG was administered at the optimum doaage for 12 hours (stage 2). Pul-
monary artery pressure (PAP, mmHg) was measured every 2 hours. At the
same time, plasma cGMP (pmol/ml) was measured to evaluate the effect of
ANP,and platelet cGMP (pmol/lOg PLT)was meaaured to evaluate the effect
of NTG. In the control phase, there were no differences in hemodynamice,
plasma cGMP,or platelet cGMP between both groupa. In theatage 1, aystolio
PAP wee significantly decreased in the two groups (NTG group, 42 & 5 to
25 +5, p < 0.01; ANP group, 44+5 to 25 + 5, p < 0.01). Platelet cGMP in
the NTG group (0.76+ 0.12 to 2.42 * 0.24), and plaama cGMP in the ANP
group (from 8 + 2 to 36 + 9) were significantly incraased. However, in the
atage 2, PAP waa increased from 26 * 4 to 36 + 4 (p < 0.01), and platelet
cGMP was decreaaed from 2.42+ 0.24 to 1.41 + 0.11 (p< 0.01) in the NTG
group. In contrast, in the ANP group, PAP and plasma cGMP remained at
the values obaerved in the stage I (PAP: 25 + 5 to 26 + 5; plaama cGMP: 36
+ 8 to 40 + 6). Conclusion: Carperitide (ANP) improved hemodynamics in
patients with acute heart failure in the absence of development of tolerance
during continuous infusion.
